The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis C

Journal of Viral Hepatitis

Volumn 10, Issue 1, 2003, Pages 16-22

  Myers, R P ^a   Patel, K ^b   Pianko, S ^b   Poynard, T ^a   McHutchison, John G ^b,c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c Division of Gastroenterology and Hepatology   (United States)

Author keywords

Fibrosis rate; Hepatitis C; Interferon; Response; Treatment

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; AGE; AGED; ARTICLE; CHRONIC HEPATITIS; DISEASE COURSE; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; AGED; ANTIVIRAL AGENTS; COHORT STUDIES; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0344643420     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.2003.00387.x     Document Type: Article

References (30)

1. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345 (1): 41-52.
2. Thevenot T, Regimbeau C, Ratziu V, Leroy V, Opolon P, Poynard T. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 update. J Viral Hepat 2001; 8 (1): 48-62.
3. Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352 (9138): 1426-1432.
4. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339 (21): 1485-1492.
5. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358 (9286): 958-965.
6. Fried MW, Shiffman ML, Reddy RK et al. Pegylated (40 kDa) interferon alfa-2a (PEGASYS) in combination with ribavirin: efficacy and safety results from a phase III, randomized. actively-controlled, multicenter study (Abstract). Gastroenterology 2001; 120 (suppl): A55.
7. Barnes E, Webster G, Whalley S, Dusheiko G. Predictors of a favorable response to alpha interferon therapy for hepatitis C. Clin Liver Dis 1999; 3 (4): 775-791.
8. Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J. Is an 'a la carte' combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology 2000; 31 (1): 211-218.
9. Tsubota A, Chayama K, Ikeda K et al. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology 1994; 19 (5): 1088-1094.
10. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001; 34 (5): 730-739.
11. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC. METAVIR. CLINIVIR. and DOSVIRC groups. Lancet 1997; 349 (9055): 825-832.
12. Seeff LB, Miller RN, Rabkin CS et al. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 2000; 132 (2): 105-111.
13. Seeff LB, Hollinger FB, Alter HJ et al. Long-term mortality and morbidity of transfusion-associated non-A, non- B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study. Hepatology 2001; 33 (2): 455-463.
14. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999; 340 (16): 1228-1233.
15. Wiese M, Berr F, Lafrenz M, Porst H, Oesen U. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in germany: a 20-year multicenter study. Hepatology 2000; 32 (1): 91-96.
16. Vogt M, Lang T, Frosner G et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999; 341 (12): 866-870.
17. Koretz RL. Making end points meet. Gastroenterology 1999; 116 (5): 1266-1267.
18. Koretz RL. Decisions, decisions, decisions. Gastroenterology 2000; 118 (6): 1268-1270.
19. Tong MJ, Blatt LM, McHutchison JG, Co RL, Conrad A. Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997; 26 (6): 1640-1645.
20. Stuyver L, Rossau R, Wyseur A et al. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993; 74 (Pt 6): 1093-1102.
21. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group, Hepatology 1996; 24 (2): 289-293.
22. National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology 1997; 26 (3 Suppl 1): 2S-10S.
23. Nelson DR, Lauwers GY, Lau JY, Davis GL. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology 2000; 118 (4): 655-660.
24. Friedman SL, Maher JJ, Bissell DM. Mechanisms and therapy of hepatic fibrosis: report of the AASLD Single Topic Basic Research Conference. Hepatology 2000; 32 (6): 1403-1408.
25. Wong JB, Poynard T, Ling MH, Albrecht JK, Pauker SG. Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group. Am J Gastroenterol 2000; 95 (6): 1524-1530.
26. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000; 90 (10): 1562-1569.
27. Fattovich G, Giustina G, Degos F et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112 (2): 463-472.
28. Khan MH, Farrell GC, Byth K et al. Which patients with hepatitis C develop liver complications? Hepatology 2000; 31 (2): 513-520.
29. Bruden D, McMahon B, Hennessy T et al. Estimating the date of hepatitis C virus (HCV) infection among Alaska native blood transfusion recipients and intravenous drug users (IDU): comparison between data from patient interviews and antibody tests using stored sera (Abstract). Hepatology 2001; 34 (4. Pt 2): 343A.
30. Forns X, Ampurdanes S, Sanchez-Tapias JM et al. Long-term follow-up of chronic hepatitis C in patients diagnosed at a tertiary-care center. J Hepatol 2001; 35 (2): 265-271.